Abstract:ABSTRACT The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous env sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential N -linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1 env evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens. IMPORTANCE The pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope ( env ). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance to VRC13. This suggests that VRC13-class bNAbs may be refractory to rapid escape and attractive for therapeutic applications. Furthermore, the identification of longitudinal viral changes concomitant with the development of neutralization breadth may help identify the viral intermediates needed for the maturation of VRC13-like responses and the design of lineage-based immunogens.

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation

Parallel HIV-1 fitness landscapes shape viral dynamics in humans and macaques that develop broadly neutralizing antibodies.

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1

Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

Host-pathogen coevolution and the emergence of broadly neutralizing antibodies in chronic infections

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

The Route of HIV Escape from Immune Response Targeting Multiple Sites Is Determined by the Cost-Benefit Tradeoff of Escape Mutations

HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies

A binary trait model reveals the fitness effects of HIV-1 escape from T cell responses

Mathematical modeling of escape of HIV from cytotoxic T lymphocyte responses

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Genetic signatures in the highly virulent subtype B HIV-1 conferring immune escape to V1/V2 and V3 broadly neutralizing antibodies

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines